Aortic Stent Grafts Market

The aortic stent grafts market is anticipated to expand from US$ 2.62 billion in 2024 to US$ 4.03 billion by 2031, with a projected CAGR of 6.5% from 2025 to 2031.

Market Insights and Analyst Perspective:

A stent graft is a specialized medical device intended for the treatment of aortic aneurysms using minimally invasive endovascular techniques. This device consists of a thin metal mesh known as the stent, which is covered by a thin polyester fabric referred to as the graft. It is introduced via a catheter and positioned within the aorta. Once positioned, the stent graft remains fixed, allowing blood to flow through it, thereby safeguarding the affected section of the aorta and preventing aneurysm rupture. The rising incidence of aortic aneurysms and the growing preference for minimally invasive procedures like endovascular repairs are key factors propelling the growth of the aortic stent grafts market. However, product recalls by market players pose challenges to market expansion. Additionally, advancements in technology and strategic initiatives by manufacturers are expected to introduce new trends in the aortic stent grafts market in the near future.

Factors Driving Growth:

Advancements in medical science and technology have led to the development of minimally invasive devices, which replace traditional, painful surgical methods with less invasive or noninvasive alternatives. Minimally invasive techniques have become increasingly popular in surgical disciplines, including cardiac surgery. Endovascular aneurysm repair (EVAR) is a minimally invasive approach for treating abdominal aortic aneurysms, performed by inserting a stent graft into the affected area of the aorta through a smaller incision than that required for open cardiac surgery, thus promoting quicker healing and reducing procedure duration. A study published by JAMA Network in May 2022 compared the long-term outcomes of EVAR with open repair of AAA, indicating that endovascular repair carries a lower risk than open repair for abdominal aortic aneurysms. Furthermore, surgeons are adopting minimally invasive techniques due to their advantages, and improvements in medical devices and surgical expertise have facilitated broader acceptance. Consequently, healthcare institutions are investing in training their medical personnel and acquiring the necessary equipment to address the rising demand for elective aortic aneurysm repair surgeries, thereby enhancing treatment options and overall healthcare experiences for patients.

Thus, the growing demand for minimally invasive devices is a significant driver of the aortic stent grafts market growth.

Strategic Insights

Report Segmentation and Scope:

The global aortic stent grafts market analysis to 2031 has been conducted by examining the following segments: product type and end user.

Segmental Analysis:

By product type, the market is divided into abdominal aortic and thoracic aortic stent grafts. The abdominal aortic stent graft segment accounted for the largest share of the aortic stent grafts market in 2023.

Regarding end users, the market is categorized into hospitals and ambulatory surgical centers. The hospital segment is expected to capture a significant market share from 2023 to 2031, due to the availability of specialized and complex scientific instruments.

Regional Analysis:

The global aortic stent grafts market report encompasses North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

In terms of revenue, North America led the aortic stent grafts market in 2023. The increasing prevalence of aortic aneurysms, attributed to a high number of smokers and a strong preference for minimally invasive procedures, along with favorable reimbursement policies and rising healthcare expenditures in the US, are key factors driving market growth in the region. For example, data from the Centers for Disease Control and Prevention (CDC) published in September 2021 indicates that a history of smoking accounts for approximately 75% of abdominal aortic aneurysms, and men aged 65 and older with a smoking history are advised to undergo abdominal aortic aneurysm ultrasound screening, even if asymptomatic, by the U.S. Preventive Services Task Force. Additionally, the Society for Vascular Surgery (SVS) reports that around 200,000 individuals are diagnosed with AAA in the US annually. Therefore, the increasing incidence of cardiovascular issues such as aortic aneurysms among the population is driving the demand for aortic stent grafts in the US, facilitating the growth of the aortic stent grafts market.

Aortic Stent Grafts Market Report Scope

Industry Developments and Future Opportunities:

The forecast for the aortic stent grafts market can assist stakeholders in planning their growth strategies. According to press releases from key market players, several initiatives are highlighted below:

1. In September 2023, MicroPort Endovastec received approval from the Thailand Food and Drug Administration (TFDA) for three aortic intervention products, including the Castor Branched Aortic Stent-Graft and Delivery System, the Minos Abdominal Aortic Stent-Graft and Delivery System, and the Hercules Thoracic Stent Graft System with Low Profile Delivery System. These products are designed to treat thoracic and abdominal aortic diseases and are now registered for use in Thailand.
2. In March 2023, Bolton Medical, Inc. obtained U.S. Food & Drug Administration (FDA) approval for its RelayPro Thoracic Stent-Graft System, which includes a delivery catheter and tube-shaped implants made of nitinol, polyester, and platinum-iridium, used for repairing damage in the aorta, particularly in the descending thoracic aorta.
3. In March 2023, Vector Biolabs announced the completion of a facility expansion, which includes office space, warehouses, QC labs, and a cleanroom manufacturing suite. The company stated that this additional capacity will enable it to maintain fast response times as demand grows and expand its offerings to include new product characterization and quality control services.
4. In May 2021, Endologix LLC launched the ALTO Abdominal Stent Graft in Canada after receiving approval from Health Canada, and it has also been commercially approved in Argentina. This launch aims to enhance the company's global presence in the market.

Competitive Landscape and Key Companies:

Key players in the aortic stent grafts market include ENDOLOGIX INC, Terumo Corporation, Radcliffe Medical Media, Cook, MicroPort Scientific Corporation, Corcym, LeMaitre Vascular, Inc, W. L. Gore & Associates, Inc., JOTEC GmbH, and Medtronic. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global consumer demand and broaden their specialty product portfolios.

This product will be delivered within 3-5 business days.